Extended Induction of Mirikizumab Sustains Efficacy and Safety Over 104 Weeks for Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Initial Induction

被引：0
|
作者：
D'Haens, Geert [1 ]
Navabi, Seyedehsan [2 ]
Chan-Diehl, Faye [3 ]
Moses, Richard E. [3 ]
Walter, James [4 ]
Gibble, Theresa Hunter [3 ]
Laharie, David [5 ]
Gisbert, Javier P. [6 ]
Vermeire, Severine [7 ]
Kobayashi, Taku [8 ]
Regueiro, Miguel [9 ]
Johns, Jordan [3 ]
Charabaty, Aline [10 ]
机构：
[1] Univ Amsterdam, Med Ctr, Amsterdam, Noord Holland, Netherlands
[2] United Med Doctors, Long Beach, CA USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Einstein Healthcare Network, Philadelphia, PA USA
[5] Ctr Hosp Univ Bordeaux, Bordeaux, France
[6] Hosp Univ La Princesa, Madrid, Spain
[7] Univ Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium
[8] Kitasato Univ, Ctr Adv IBD Res & Treatment, Kitasato Inst Hosp, Tokyo, Japan
[9] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA
[10] Johns Hopkins Sch Med, Potomac, MD USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1139
引用
收藏
页码：S871 / S872
页数：2
相关论文
共 50 条
  • [1] EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
    D'Haens, Geert
    Higgins, Peter D.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard
    Redondo, Isabel
    Escobar, Rodrigo
    Morris, Nathan
    Kobayashi, Taku
    GASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1086
  • [2] Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
    D'Haens, G.
    Higgins, P. D. R.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Lee, S.
    Moses, R. E.
    Redondo, I.
    Escobar, R.
    Morris, N.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 682 - 682
  • [3] Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis
    Sturm, A.
    Sebastian, S.
    Faye, A. S.
    Armuzzi, A.
    Buisson, A.
    Halfvarson, J.
    Zeissig, S.
    Kochar, B.
    Maier, S.
    Redondo, I
    Moses, R. E.
    Keohane, A.
    Watanabe, K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2005 - i2006
  • [4] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
    Sandborn, W. J.
    Ferrante, M.
    Bhandari, B. R.
    Berliba, E.
    Hibi, T.
    D'Haens, G. Geert R.
    Tuttle, J.
    Krueger, K.
    Friedrich, S.
    Durante, M.
    Arora, V.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
  • [5] Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    D'Haens, Geert
    Higgins, Peter D. R.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard E.
    Redondo, Isabel
    Escobar, Rodrigo
    Gibble, Theresa Hunter
    Keohane, Anthony
    Morris, Nathan
    Zhang, Xin
    Arora, Vipin
    Kobayashi, Taku
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2335 - 2346
  • [6] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [7] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
    Andrews, J. M.
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
  • [8] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214
  • [9] Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and-2 trials
    Rubin, D. T.
    Charabaty, A.
    Jairath, V.
    Walter, J.
    McGinnis, K.
    Moses, R.
    Maier, S.
    Escobar, R.
    Baygani, S.
    Zaremba-Pechmann, L.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1641 - I1642
  • [10] EXTENDED INDUCTION RESPONSE OVER TIME IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB IN THE LUCENT-1 AND-2 TRIALS
    Rubin, David T.
    Charabaty, Aline
    Jairath, Vipul
    Walter, James
    McGinnis, Kim
    Moses, Richard
    Maier, Sebastian
    Escobar, Rodrigo
    Baygani, Simin
    Zaremba-Pechmann, Liliana
    Kobayashi, Taku
    GASTROENTEROLOGY, 2024, 166 (05) : S821 - S821
12345